Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery : The MISSION-1 randomized controlled trial
Copyright © 2021 Elsevier Inc. All rights reserved..
BACKGROUND: Studies found that patients who underwent coronary artery bypass grafting (CABG) often fail to receive optimal evidence-based secondary prevention medications. We evaluated the effectiveness of a smartphone-based quality improvement effort on improving the prescription of medical therapies.
METHODS: In this cluster-randomized controlled trial, 60 hospitals were randomized to a control arm (n = 30) or to an intervention arm using smartphone-based multifaceted quality improvement interventions (n = 30). The primary outcome was the prescription of statin. The secondary outcomes were prescription of beta-blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker (ACE inhibitor or ARB), and optimal medical therapy for eligible patients.
RESULTS: Between June 1, 2015 and September 15, 2016, a total of 10,006 CABG patients were enrolled (5,653 in 26 intervention and 4,353 in 29 control hospitals, 5 hospitals withdrew). Statin prescribing rate was 87.8% in the intervention arm and 84.4% in the control arm. We saw no evidence of an effect of intervention on statin prescribing in the intention-to-treat analysis (odds ratio [OR], 1.31; 95% confidence interval (CI), 0.68-2.54; P = .43) or in key patient subsets. The prescription rates of ACE inhibitor or ARB and optimal medical therapy were comparable between study groups, while beta-blocker was more often prescribed in the intervention arm. Post hoc analysis demonstrated a greater increase in statin prescribing rate over time in the intervention arm.
CONCLUSIONS: A smartphone-based quality improvement intervention compared with usual care did not increase statin prescribing for patients who received CABG. New studies focusing on the best practice of this technique may be warranted.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:237 |
---|---|
Enthalten in: |
American heart journal - 237(2021) vom: 08. Juli, Seite 79-89 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Qu, Jianyu [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.08.2021 Date Revised 24.08.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ahj.2021.03.005 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322468515 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322468515 | ||
003 | DE-627 | ||
005 | 20231225182113.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ahj.2021.03.005 |2 doi | |
028 | 5 | 2 | |a pubmed24n1074.xml |
035 | |a (DE-627)NLM322468515 | ||
035 | |a (NLM)33689732 | ||
035 | |a (PII)S0002-8703(21)00070-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Qu, Jianyu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery |b The MISSION-1 randomized controlled trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.08.2021 | ||
500 | |a Date Revised 24.08.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
520 | |a BACKGROUND: Studies found that patients who underwent coronary artery bypass grafting (CABG) often fail to receive optimal evidence-based secondary prevention medications. We evaluated the effectiveness of a smartphone-based quality improvement effort on improving the prescription of medical therapies | ||
520 | |a METHODS: In this cluster-randomized controlled trial, 60 hospitals were randomized to a control arm (n = 30) or to an intervention arm using smartphone-based multifaceted quality improvement interventions (n = 30). The primary outcome was the prescription of statin. The secondary outcomes were prescription of beta-blocker, angiotensin-converting enzyme inhibitor, or angiotensin receptor blocker (ACE inhibitor or ARB), and optimal medical therapy for eligible patients | ||
520 | |a RESULTS: Between June 1, 2015 and September 15, 2016, a total of 10,006 CABG patients were enrolled (5,653 in 26 intervention and 4,353 in 29 control hospitals, 5 hospitals withdrew). Statin prescribing rate was 87.8% in the intervention arm and 84.4% in the control arm. We saw no evidence of an effect of intervention on statin prescribing in the intention-to-treat analysis (odds ratio [OR], 1.31; 95% confidence interval (CI), 0.68-2.54; P = .43) or in key patient subsets. The prescription rates of ACE inhibitor or ARB and optimal medical therapy were comparable between study groups, while beta-blocker was more often prescribed in the intervention arm. Post hoc analysis demonstrated a greater increase in statin prescribing rate over time in the intervention arm | ||
520 | |a CONCLUSIONS: A smartphone-based quality improvement intervention compared with usual care did not increase statin prescribing for patients who received CABG. New studies focusing on the best practice of this technique may be warranted | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Randomized Controlled Trial | |
650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
700 | 1 | |a Du, Junzhe |e verfasserin |4 aut | |
700 | 1 | |a Rao, Chenfei |e verfasserin |4 aut | |
700 | 1 | |a Chen, Sipeng |e verfasserin |4 aut | |
700 | 1 | |a Gu, Dachuan |e verfasserin |4 aut | |
700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Heng |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Yan |e verfasserin |4 aut | |
700 | 1 | |a Hu, Shengshou |e verfasserin |4 aut | |
700 | 1 | |a Zheng, Zhe |e verfasserin |4 aut | |
700 | 0 | |a MISSION-1 Collaborative Group |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t American heart journal |d 1945 |g 237(2021) vom: 08. Juli, Seite 79-89 |w (DE-627)NLM000012270 |x 1097-6744 |7 nnns |
773 | 1 | 8 | |g volume:237 |g year:2021 |g day:08 |g month:07 |g pages:79-89 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ahj.2021.03.005 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 237 |j 2021 |b 08 |c 07 |h 79-89 |